Mercury Biopharmaceutical Corporation (TPEX:6932)

Market Cap	3.72B
Revenue (ttm)	4.96M
Net Income (ttm)	-50.57M
Shares Out	421.85M
EPS (ttm)	-0.12
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	259,254
Average Volume	322,204
Open	8.99
Previous Close	8.91
Day's Range	8.61 - 8.99
52-Week Range	8.49 - 17.45
Beta	-2.76
RSI	33.62
Earnings Date	Aug 7, 2025

About Mercury Biopharmaceutical

Mercury Biopharmaceutical Corporation engages in the development of drugs for unmet needs in Taiwan. The company develops StackDose platform, a drug development platform to produce new dosage forms with precise time-controlled dissolution, precise site absorption, and various dosage adjustments to enhance the bio-availability of active pharmaceutical ingredients to reduce the dosage of drugs and its side effects. It develops drugs for treating erectile dysfunction, pulmonary hypertension, sleep disorder, benign prostatic hyperplasia, angina pec...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2019
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6932

Financial Performance

In 2024, Mercury Biopharmaceutical's revenue was 4.96 million, an increase of 380.45% compared to the previous year's 1.03 million. Losses were -50.57 million, 15.4% more than in 2023.